

# ANTEOTECH RAISES A\$3.5 MILLION TO ACCELERATE COMMERCIALISATION OF LIFE SCIENCES AND ADVANCED BATTERY TECHNOLOGIES

BRISBANE, AUSTRALIA, 27 January 2026: AnteoTech Ltd (ASX: ADO) (AnteoTech or the Company) is pleased to announce the following:

- Successful capital raise of A\$3.5 million (net of costs) through a placement of new fully paid ordinary shares at A\$0.0155 (1.55 cents) per share to institutional, sophisticated and professional investors (Placement).
- Each participant in the Placement will receive attaching options, on the following basis, for every two (2) Placement Shares issued:
  - One (1) free attaching option in an existing class of listed options, exercisable at A\$0.035 (3.5 cents) and expiring on 31 May 2026 (Listed Options); and
  - One (1) free attaching option in a new class of unlisted options, exercisable at A\$0.035 (3.5 cents) and expiring 31 January 2028 (Unlisted Options).
- The Placement received strong investor support and was scaled back.
- Placement price of \$0.0155 (1.55 cents) represents a 20.8% discount to the 30-day VWAP, 24.6% discount to the 15-day VWAP and 26.2% discount to the last traded price.
- Pro-forma cash balance A\$6.6 million (as of 30 September 2025) following completion of the Placement.
- Funds to accelerate commercialisation of Life Sciences and Advanced Battery Technology (ABT) products and technologies globally.
- Funding supports revenue growth initiatives and strategic partnership development.
- Near-term targets for 2H FY26 include:
  - Conversion of current ABT and Life Sciences potential customer trials to initial commercial supply agreements, including for new product, Anteo S.
  - Trialling and initial commercial supply into the US market of the joint product developed with Black Diamond Structures (BDS) (ASX announcement 25 Sept 2025).
  - Progression of strategic partnership discussions in the drone, wearable and EV battery segments.
  - New Life Sciences customer conversions in India and new diagnostic product development and 'go to market' commercial agreements.

## Capital raised to accelerate sales growth and strategic partnerships

AnteoTech has completed the Placement to support the acceleration of sales revenue growth through further commercialisation of:

- **Life Sciences - AnteoBind NXT™** in the lateral flow and Luminex In Vitro Diagnostics (IVD) markets globally, with a particular focus on India; as well as in new IVD markets; namely Chemiluminescence Immunoassays (CLIA) and Enzyme-Linked Immunosorbent Assay (ELISA) through joint product development and market entry commercial agreements, and
- **Advanced Battery Technologies - Anteo X™ and Ultranode™** products for high silicon Lithium ion Batteries (LiB) in drones, wearables and consumer applications.

The Company continues discussions regarding a strategic partnership in the Electric Vehicle (EV) sector in relation to Ultranode X™, which has achieved a milestone of more than 1,000 cycles at 80% capacity (ASX announcement 17 November 2025).





Sales conversion initiatives for Anteo S, a new AnteoTech product, designed for use in ceramic-coated LiB separators, are also progressing.

The Company's program to identify global strategic partners for new product development across both the Life Sciences and ABT businesses, as well as in relation to the Company's core technology in new markets, will be accelerated through the Placement funding.

Recent ASX announcements on the Life Sciences business (ASX announcement 29 December 2025) and ABT business (ASX announcement 19 January 2026) provide further detail on current commercial activities.

AnteoTech's strategy, released in June 2025 (ASX announcement 10 June 2025), focuses on revenue growth, geographic expansion driven by market end use demand and continued cost discipline (see Figure 1 below). As part of this strategy, the Company has expanded its sales capability, with two sales personnel recently joining the business.

## June 2025 Strategy by Target Markets

		Existing markets where opportunities will continue to be pursued	New opportunities to be targeted and pursued
Strategy			
		Life Sciences	Advanced Battery Technologies
India		<ul style="list-style-type: none"> <li>Drive targeted sales growth through existing network facilitated by <b>expansion of our commercialisation pipeline</b>.</li> <li>Securing of strategic partnerships based on mutually beneficial, profit repatriation model basis).</li> </ul>	<ul style="list-style-type: none"> <li>Further expand through the <b>Serum Institute of India relationship</b> and secure <b>additional similar customers</b>.</li> <li>Expand pipeline working with <b>Austrade &amp; Trade &amp; Investment Queensland (TIQ)</b>.</li> </ul>
USA		<ul style="list-style-type: none"> <li>Expansion of our customer base <b>Attract a strategic partner</b></li> </ul>	<ul style="list-style-type: none"> <li>Target the <b>Point-of-Care Diagnostics, Particle and Plate markets</b>.</li> </ul>
South Korea & Japan		<ul style="list-style-type: none"> <li>Expand our customer base/sales.</li> <li>Attract <b>strategic partners</b></li> </ul>	<ul style="list-style-type: none"> <li>Grow market presence through our <b>distributor</b>.</li> <li>Expand sales pipeline with support from <b>Austrade and TIQ</b>.</li> </ul>
Europe		<ul style="list-style-type: none"> <li>Expand existing customer base <b>attract strategic partners</b></li> </ul>	<ul style="list-style-type: none"> <li>Re-engage with <b>global Life Sciences companies across Particle and Plate markets</b>.</li> </ul>
26 November 2025 ©AnteoTech Limited			

**Figure 1. AnteoTech's Strategy by business and jurisdiction**

(Source: MD/CEO's AGM presentation ASX Announcement 26 November 2025)

### MERRILL GRAY, MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER OF ANTEOTECH COMMENTED:

*"I would like to thank existing shareholders who supported the Company in this capital raise and welcome new shareholders to the Company. AnteoTech is entering a highly focused commercial phase across both Life Sciences and Advanced Battery Technologies.*

*Following the achievement of recent technical and product development milestones, this funding provides the capacity to accelerate sales initiatives and progress strategic discussions by supporting qualification and engagement programs, leading to the securing of new sales and partnerships globally in CY2026."*



## Use of Funds

Use of Funds	Placement \$3.5M
Sales and Business Development	1,400
Strategic Partnerships	350
Materials for product sales & development	350
Technical product development & enhancements	525
R&D – new products and applications	175
Working Capital	700
<b>Net Capital before costs of the offer</b>	<b>3,500</b>

The above Use of Funds table is based on current estimates and may be varied by the Company.

## Details of the Placement

The Company has received firm commitments totalling A\$3.5 million (net of costs) for new fully paid ordinary shares in the Company at A\$0.0155 (1.55 cents) per share

Key terms of the Placement are as follows:

- 245,699,993 million Placement Shares at A\$0.0155 (1.55 cents) cents per Placement Share to raise A\$3.5 million, net of costs;
- The issue price of the Placement Shares represents a:
  - 20.8% discount on the 30-day volume weighted average price (**VWAP**)
  - 24.6% discount to the 15-day VWAP and
  - 26.2% discount on the last traded price
- 122,849,996 Listed Class Options and 122,849,996 Unlisted Options will be issued, approximately.
- The Placement was made to investors in Australia who qualified as professional or sophisticated investors under the requirements of the Corporations Act 2001 (Cth) and sophisticated and professional investors in select other jurisdictions.
- Placement Shares will rank equally with existing ordinary shares of the Company;
- The Placement Shares will be issued on or about 2 February 2026, under the Company's available placement capacity under ASX Listing Rule 7.1A.
  - Each participant in the Placement will receive two (2) free attaching options for every two (2) shares issued under the Placement.
  - Half the Options will be issued under the existing class of Listed Options with an exercise Price of A\$0.035 (3.5 cents) and an expiry date of 31 May 2026. Half the Options will be issued under a new class of securities with an exercise price of A\$0.035 (3.5 cents) and expiring 31 January 2028.
  - The Options will be issued from available placement capacity under ASX Listing Rule 7.1.

MST Financial Services Pty Ltd and Alpine Capital Pty Ltd acted as Joint Lead Managers for the Placement. They will receive a combined 6% fee and one Option for every eight new shares issued, split equally between Listed Class Options and Unlisted Options. Broker Options will be issued from available placement capacity under ASX Listing Rule 7.1.

## Capital Raise Timetable

Event	Date
<b>ASX Announcement of Placement and Entitlement Offer</b>	<b>Tuesday 27 January 2026</b>
Settlement of Placement Shares	Monday 2 February 2026
<b>Expected date of ASX Quotation of New Shares and Options under the Placement</b>	<b>Tuesday 3 February 2026</b>

This timetable is indicative. The Company reserves the right to vary these times and dates.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

**Media and investor enquiries:** on +61 7 3219 0085 or [investors@anteotech.com](mailto:investors@anteotech.com)

**Company and Partnering enquiries:** Merrill Gray, CEO/MD, on + 61 7 3219 0085

For further information, please check our website [www.anteotech.com](http://www.anteotech.com)

## About AnteoTech - (ASX: ADO)

AnteoTech is a supplier of advanced material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemistry platform technology to develop and commercialise solutions for our global customer base. From our patented cross linker product Anteo X™ and Separator coating product Anteo S to our next-generation high silicon anode formulations, Ultranode™, our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable materials within the global battery market. Our Life Sciences business supplies advanced activation materials through our AnteoBind™ suite of products to leading developers and manufacturers of vaccines and diagnostic tests. Our products deliver more sensitive and reproducible results and on incorporation in 'point of care' tests, enable faster, more reliable and accurate test results wherever they are needed.

## AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at [www.anteotech.com](http://www.anteotech.com) and subscribe to receive our email alert service.

## Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech' business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.